Skip to main
HUM

Humana (HUM) Stock Forecast & Price Target

Humana (HUM) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 28%
Hold 61%
Sell 0%
Strong Sell 0%

Bulls say

Humana's increased earnings per share (EPS) estimate for 2025, revised upwards to $17.06 from $16.26, reflects strong second-quarter results and updated guidance, indicating robust financial performance. The company anticipates year-over-year earnings growth for 2027, supported by the implementation of margin initiatives, despite expecting no recovery of bonus payments related to their star rating program. Additionally, Humana's strong competitive position is reinforced by its above-industry star rating in the Medicare Advantage program, which positions the company favorably amid ongoing regulatory and reimbursement changes.

Bears say

Humana's outlook is precarious primarily due to anticipated declines in earnings per share (EPS) for 2026, which are projected to drop slightly from 2025 levels despite management's margin improvement initiatives. The company faces multiple downside risks, including increased competition in Medicare Advantage (MA), inadequate reimbursement rates, and declining MA Star ratings, which could further jeopardize its financial performance. Additionally, there is a concerning expectation that the necessity for increased investments to support Stars recovery could result in FY27 EPS falling approximately 10% short of current estimates.

Humana (HUM) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 28% recommend Buy, 61% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humana (HUM) Forecast

Analysts have given Humana (HUM) a Hold based on their latest research and market trends.

According to 18 analysts, Humana (HUM) has a Hold consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $294.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $294.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humana (HUM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.